Biopharma Genomic Testing Market Research

Primary Research

• Conducted telephone interviews with biopharma stakeholders director level and above involved in oncology R&D (translational and clinical research)
• Conducted telephone interviews with biopharma CDx stakeholders director level and above (e.g., vice president of biomarker strategy)
• Interviews were split by biopharma size with a majority at large biopharma

DeciBio delivered a virtual final presentation that covered an in depth quantitative market analysis (e.g., landscape today, key trends, and expected future growth)

Quantitative assessment included:

• Share of clinical trials employing prospective and / or retrospective genomic tests
• Frequency of tests (e.g., therapy selection, MRD, treatment response monitoring) per patient
• Test utilization by sample type, panel size, and (de)centralized models